ARDX Earnings

ARDX reported its earnings on 2026-04-30, showcasing a revenue of 94.47M against an estimate of 93.28M, resulting in a 1.28% surprise. The EPS was -0.15, surpassing the expected -0.13 by -15.38%. The stock experienced a 8.69% price change on the earnings day and a 12.16% change over the next five days, reflecting market reactions to the results.

Following ARDX's earnings announcement on 2026-04-30, the stock price moved by 8.69% on the day of the release. Over the subsequent five days, it saw a 12.16% change. Historically, ARDX's stock price tends to shift by an average of -3.5% in the 10 days leading up to earnings and 1.5% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate ARDX's annual revenue to reach 116.25M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between ARDX's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, ARDX's stock price typically moves by -3.5% in the 10 days before its earnings and 1.5% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of -0.04 and revenue of 116.25M.

The earnings call summary and Q&A session reveal strong financial performance, with a 32% increase in total dispenses and 19% in paid prescriptions, despite a market decline. Management's optimistic guidance, steady OpEx, and improved fulfillment rates support growth projections. The positive outlook for IBSRELA and XPHOZAH revenues, along with strategic investments, outweigh concerns about competition and enrollment pace. Given the market cap of $1.52 billion, these factors suggest a positive stock price movement of 2% to 8% over the next two weeks.